Modification of Parkinsonism--chronic treatment with L-dopa.
D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001806:Blood Urea Nitrogen; D001812:Blood-Brain Barrier / Q000187:drug effects; D002908:Chronic Disease; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism / Q000633:toxicity / Q000652:urine; D004298:Dopamine / Q000652:urine; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy; D008297:Male; D008345:Manganese / Q000097:blood; D008606:Mental Processes / Q000187:drug effects; D008750:Methyldopa / Q000008:administration & dosage; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D009461:Neurologic Manifestations; D010300:Parkinson Disease / Q000188:drug therapy*; D010648:Phenylacetates / Q000652:urine; D010919:Placebos; D013960:Thyroid Function Tests; D014443:Tyrosine / Q000378:metabolism; D014839:Vomiting / Q000139:chemically induced
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D010648:Phenylacetates; D010919:Placebos; D014443:Tyrosine; D008345:Manganese; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D004298:Dopamine